Activin A

Overview

Activin A is the homodimeric form of activin composed of two inhibin βA subunits linked by a disulfide bond. It is the most abundant and best-studied member of the activin family within the TGF-β superfamily of growth and differentiation factors. First purified independently by two groups in 1986 — one searching for the ovarian factor that stimulated FSH release (the "activin" of follicle-stimulating hormone releasing protein nomenclature) and one searching for an erythroid differentiation factor (EDF) — activin A's identity was reconciled when sequencing revealed that both activities resided in the same molecule.

Activin A operates as the functional counterweight to inhibin in the reproductive endocrine axis: where inhibin suppresses FSH secretion, activin A stimulates it. Beyond reproduction, activin A has been implicated in embryonic mesoderm induction, wound healing, hepatic regeneration, hematopoiesis, neuronal survival, and inflammation. It is one of the most pleiotropic peptide growth factors known.

Research interest in activin A spans developmental biology, oncology (where it can act as either a tumor suppressor or promoter depending on context), reproductive endocrinology, and the emerging field of "inflammaging" — chronic low-grade inflammation associated with aging, in which activin A serum levels rise.

Structure

Activin A is a disulfide-linked homodimer of two inhibin βA subunits.

• Subunit composition: βA-βA (homodimer of inhibin βA chains)
• Mature subunit length: 116 amino acids each (after cleavage from the 426-aa precursor)
• Disulfide architecture: Single inter-chain disulfide plus intra-chain "cystine knot" topology characteristic of the TGF-β superfamily
• Molecular weight: ~26 kDa (mature dimer)
• Gene: INHBA (chromosome 7p15-p13)
• Glycosylation: N-linked glycosylation on the mature subunit

The βA subunit is structurally distinguished from the βB subunit (which forms activin B, βB-βB) and the α subunit (which pairs with βA or βB to form inhibin A or B respectively). The cystine knot fold is conserved across the entire TGF-β superfamily, including myostatin, GDF-11, BMPs, and TGF-β itself.

Mechanism of Action

Receptor Complex

Activin A signals through a heteromeric receptor complex:

• Type II receptors: ActRIIA (ACVR2A) and ActRIIB (ACVR2B) — constitutively active serine/threonine kinases
• Type I receptor: ALK4 (ACVR1B), recruited and phosphorylated upon ligand binding
• Co-receptors: None required (unlike some BMPs)

Ligand binding induces type II receptor recruitment of type I receptor; type II phosphorylates and activates type I; type I phosphorylates SMAD2 and SMAD3.

Smad Signaling

Phosphorylated SMAD2/3 forms a complex with SMAD4 (the common-mediator SMAD), translocates to the nucleus, and regulates transcription of target genes including pituitary FSHβ, follistatin, and many context-dependent targets.

Antagonism by Follistatin

Follistatin binds activin A with high affinity in a 2:1 stoichiometry, sequestering the dimer and blocking receptor access. This natural antagonism creates a tunable activin tone in tissues and is the basis for follistatin's role in muscle, reproductive, and hepatic biology.

Cross-talk with Other TGF-β Members

Myostatin, GDF-11, BMP-9, and BMP-10 share receptor subunits with activin A. This creates competitive ligand interactions that explain why activin A blockade and myostatin blockade share certain phenotypes (notably skeletal muscle hypertrophy seen with ActRIIB-Fc decoy receptors).

Cellular Effects

• Pituitary gonadotrope: Stimulates FSHβ transcription and FSH secretion
• Erythroid progenitors: Promotes terminal differentiation
• Embryonic stem cells: Maintains pluripotency in human ESCs (paradoxically); induces mesendoderm in differentiation protocols
• Hepatocytes: Inhibits proliferation, induces apoptosis (tumor suppressor role)
• Wound keratinocytes: Promotes re-epithelialization and granulation tissue
• Macrophages: Modulates polarization and cytokine production

Research Summary

Common Discussion Topics

1. Activin A vs inhibin — Sharing the βA subunit with inhibin A creates a regulatory dyad: the same subunit produces opposite effects on FSH depending on whether it pairs with α (inhibin, suppressive) or another β (activin, stimulatory). Subunit availability dictates the balance.

2. ActRIIB decoy receptors and muscle — Soluble ActRIIB-Fc fusion proteins block both activin A and myostatin, producing dramatic skeletal muscle hypertrophy in animal models. This dual blockade has informed therapeutic candidate design for muscle-wasting conditions.

3. Pluripotency paradox — In Xenopus, activin A induces mesoderm (a differentiation signal). In human embryonic stem cells, it maintains pluripotency. The same pathway produces opposite outcomes depending on cellular context, illustrating the role of co-factors and chromatin state in TGF-β signaling.

4. Inflammaging biomarker — Circulating activin A rises with chronological age and correlates with frailty, cardiovascular disease, and mortality in older cohorts. Whether activin A is a driver or merely a marker of age-related inflammation remains under investigation.

5. Follistatin counterbalance — The activin/follistatin ratio is a useful conceptual framework: tissue activity reflects free activin concentrations, which depend on follistatin binding. This explains why follistatin gene therapy and activin pathway blockade produce overlapping phenotypes.

Related Compounds

• Activin — broader entry covering the activin family
• Inhibin — heterodimer (α/βA) that opposes activin A at the FSH axis
• Follistatin — high-affinity activin-binding protein and natural antagonist
• Myostatin — TGF-β family member sharing ActRIIB with activin A